Medicinal Chemistry Research
Jagtvej 162, 2100 København Ø, 30, Bygning: 242
In my research group (Bach Group) we develop biological active small-molecule inhibitors against key CNS proteins involved in excitotoxicity and oxidative stress. We evaluate the ‘druggability’ of selected targets, and aim at developing new high-quality chemical probes useful for pharmacological studies and for identifying new therapeutic principles against ischemic stroke and related diseases.
Fragment-based drug discovery (FBDD) is a core theme of our research. We screen our library of fragments (i.e. small substructures of druglike molecules) using very sensitive biophysical methods, such as SPR and Ligand-based NMR. Promising and validated hits are optimized into lead molecules by medicinal chemistry, biostructural studies and pharmacology.
For more information about our research and open positions, please contact email@example.com